Skip to search formSkip to main contentSkip to account menu

matuzumab

Known as: humanized anti-EGFR monoclonal antibody 
A humanized monoclonal antibody with antineoplastic activity. Matuzumab binds the epidermal growth factor receptor (EGFR) with high affinity… 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (1)

Antibodies, Monoclonal, Humanized

Narrower (1)

EMD 72000
NCIt Antineoplastic Agent Terminologyantigen bindingcapecitabine/cisplatin/epirubicin/matuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer
AbstractAlthough epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) have been proved synergistic effect when… 
2012
2012
In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor.
2011
2011
Efficient Blockade of Akt signaling is a determinant factor to overcome resistance to Matuzumab
BackgroundClinical studies have shown antineoplastic effectiveness of monoclonal antibodies (MAbs) against EGFR for different… 
Review
2007
Review
2007
Antibodies to the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab
Matuzumab and panitumumab are antibodies against the epidermal growth factor receptor (EGFR) that are being evaluated in several… 
2006
2006
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data the… 
Review
2006
Review
2006
Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies
Upper gastrointestinal malignancies are major causes of morbidity and mortality worldwide. Despite the results of recent clinical… 
2005
2005
Antibody-based targeted therapy for gastric cancer
Systemic chemotherapy has been used to treat gastric cancer in Japan, Europe, and North America since the late 1950s. However… 
2005
2005
A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Mullerian malignancies
3151 Background: A high proportion of ovarian tumors express the epidermal growth factor receptor (EGFR). Preclinical and… 
2005
2005
Phase I study of the humanized anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with cisplatin, 5-fluorouracil and leucovorin (PFL) in patients (pts) with…
3156 Background: EG cancer is diagnosed in more than 60% of patients (pts) in a locally advanced or metastatic stage. In this… 
2004
2004
Technology evaluation: Matuzumab, Merck KGaA.
  • Tracy Kim
  • Current opinion in molecular therapeutics (Print)
  • 2004
  • Corpus ID: 42460815
Merck KGaA is developing matuzumab, a fully humanized epidermal growth factor receptor (EGFR)-specific monoclonal antibody, as a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)